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Abstract 
 
Tyechia L. Culmer, MS 
CB1 RECEPTOR ACTIVITY MODULATES RESPONSES IN THE FORCED SWIM TEST 
AND OPEN FIELD TEST PARADIGMS. 
(Under the direction of Linda Dykstra, PhD) 
 
Cannabinoid type I (CB1) receptor activation in the forced swim test (FST) and on 
locomotor activity (LMA) was examined by manipulating the endogenous agonist 
anandamide (AEA).  AEA modifier URB597 prevents AEA metabolism and AM404 inhibits 
the reuptake of AEA in post synaptic neurons.    
Antidepressant-like behavior was measured using time spent immobile (sec) in the 
FST, and distance traveled (cm), average velocity (cm/sec), entries into the center zone (#), 
and time spent in the center zone (min) in the open field test.  LMA before (Pre-FST1), 
immediately after (Post-FST1), and a week after the FST (LMA-FST1) were measured. 
Time spent immobile decreased with desipramine (DMI; 10 mg/kg), URB597 (1.0 
and 3.2 mg/kg), and AM404 (1.0 mg/kg).  Although 1.0 mg/kg of URB597 and AM404 
reduced time spent immobile, distance traveled was not impaired.  Overall, the decreases in 
time spent immobile were not because of LMA solely, and URB597 and AM404 have 
antidepressant properties. 
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DEDICATION 
 
To the men and women around the world that have developed stress-induced depression.  
The mechanism for the onset of this mental illness is very important and a potential therapy 
may include pharmacological manipulation of the endocannabinoid system, specifically the 
CB1 receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv
  
 
 
 
 
ACKNOWLEDGEMENTS 
 
I acknowledge the author and finisher of my life God, and my Lord and Savior Jesus Christ 
for walking with me, talking to me, petitioning to God on my behalf, and guiding me on my 
life journey.   Also, I would like to acknowledge my spiritually grounded and supportive 
parents, Ms. Evelyn L. Culmer and Mr. Everette Burrows.  Words cannot express how 
blessed I am to have parents like them.  I rely on their strength, determination, life 
experiences, and words of wisdom. In addition, I would like to acknowledge the Talton, 
Lester, Culmer, and Burrows families.    To be a Christian is to serve God by loving and 
serving others.  I am so grateful to serve God by being a member of Orange Grove 
Missionary Baptist Church, Zeta Phi Beta Sorority, Inc (Eta Phi Zeta Graduate Chapter of 
Chapel Hill), Initiative for Minority Student Diversity (IMSD), the General Alumni Association 
of the University of North Carolina at Chapel Hill, Carolina Club, Graduate Women in 
Science, College on Problems of Drug Dependence, and the Society of Neuroscience. 
Special Thank you to: the late Allie B. Lester, Margaret A. Lester, Delores Milton, Keith, 
Dale, and Brandon Lester, Karen Derby, Danielle Ford, Danielle Johnson Coats, Rosena 
Francois, Maya M. McDoom, Myrissa Garth King, Renee Brown, Leah Watson, Noelle 
Hutchins Kelso, Norma Hughes, Drs. Henry Frierson, Tonya Gerald, Pat Phelps, Patrick 
Brenwald, Ayoola Aboyade-Cole, Janelle Saulter, Ashalla Freeman, Gary Johnson, T. Ken 
Harden, Willie Wilson III, Jennifer Webster-Cyriaque, Pam Hurley, Mitchell Picker, Laurence 
Miller, Ms. Rebecca Balter, Karl Schidmit, Dana Daughtery, Michael Johnson, Dr. Adriel 
Hilton, Dr. Kudzai Chikwava, Wendy Moise, Julian McCaulay, Zuri Gay, UNC Graduate 
School and Department of Pharmacology, Christopher Turner, Kathy Justice.  
 
v 
  
 
 
 
 
 
TABLE OF CONTENTS 
 
LIST OF TABLES………………………..……………………………………………………..vii 
LIST OF FIGURES…………………………………………………………………………….viii 
LIST OF ABBREVIATIONS……………………………………………………………………ix 
  CHAPTER 
1. BACKGROUND AND SIGNIFICANCE……………………………………...1 
2. INTRODUCTION…………………………………………………………….....6 
3. MATERIALS AND METHODS………………………………………………..9 
4. RESULTS……………………………………………………………………...13 
a. EFFECT OF THE FORCED SWIM TEST ON BEHAVIORAL  
RESPONSES……………………………………………………………….....13 
b. EFFECT OF THE FORCED SWIM TEST ON LOCOMOTOR  
ACTIVITY………………………………………………………………………14 
5. DISCUSSION………………………………………………………………….16 
6. CONCLUSION…………………………………………………………..…….21 
REFERENCES………………………………………………………………..33 
APPENDIX…………………………………………………………………….37 
 
 
 
 
 
 
 
 
 
 
vi 
 LIST OF TABLES 
 
1 Locomotor activity assessment of distance traveled (cm) mean values 
(+ SEM) for treatment with vehicle, 10 mg/kg of DMI, 0.03 mg/kg-3.2  
mg/kg of URB597, and 0.1 mg/kg-3.2 mg/kg of AM404 measured in 
 the open field test (30 min session). 
…………………………………………………………...………………………………32 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii
 LIST OF FIGURES 
 
1 Schematic of Hypothalamus-Pituitary Adrenal (HPA) axis  
stress response cascade………………………………………………………………24 
 
2 Schematic representation of endocannabinoid signaling……………….…….…...25 
3 Effects of 10 mg/kg and 20 mg/kg desipramine (DMI) on time spent  
immobile in FST1 (25° C)………………………………………………………….…..26   
 
4 Effects of URB597 on time spent immobile in FST1 (25° C)………….…….…..…27   
5 Effects of AM404 on time spent immobile in FST1 (25° C)..…………..……...…..28 
6 Effects of DMI on distance traveled in the open field test………………………....29 
7 Effects of URB597 on distance traveled in the open field test……………...........30 
8 Effects of AM404 on distance traveled in the open field test……………....…......31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 LIST OF ABBREVIATIONS 
 
2-arachidonoyl glycerol………………………………………………………………….....2-AG 
Adenylate cyclase…………………………………………………….……………………….AC 
Adenosine triphosphate………………………………………………………………….….ATP 
Adrenocorticotropic hormone……………………………………………………………..ACTH 
AEA metabolism inhibitor……………………………………………………………....URB597 
AEA reuptake inhibitor………………………………………………….………………...AM404 
Anandamide…………………………………………………………….……………….……AEA 
Calcium…………………………………………………………………….………….………Ca2+ 
Cannabinoid type 1 receptor………………………………………………………………...CB1 
Cannabinoid type 2 receptor………………………………..………………………….….. CB2 
Corticosterone……………………………………………………………………..…..…..CORT 
Corticotropin releasing hormone…………………………………………………………...CRH 
Cyclic adenosine monophosphate………………………………………….…………….cAMP 
Desipramine…………………..………………………………………………………….…...DMI 
Elevated plus maze………………………………………………………………………….EPM 
Fatty acid amide hydrolase……………………………………………………….……….FAAH 
Forced swim test…………………………………………………………………….……….FST 
Gamma-aminobutyric acid………………………………………………….…………….GABA 
Hypothalamus Pituitary Adrenal……………………………………………………………HPA 
Intraperitoneal…………………………………………………………………………………...IP 
Locomotor activity chamber…………………………………………………..…………….LAC 
Locomotor activity…………………………………………………………………………....LMA 
Monoamine oxidase inhibitor………………………………………………………….....MAO-I 
ix 
 N-acylphosphatidyl enthanolamine………………………………………………………NAPE 
Paraventricular nucleus………………………………………………………………….….PVN 
Potassium……………………………………………………………………………….……....K+ 
Selective serotonin reuptake inhibitor…………………………………………………….SSRI 
Tricyclic anti-depressant…………………………………………………………………….TCA 
Delta-9 tetrahydrocannabinol……………………………………………………………….THC 
Tail suspension test………………………………………………………………………….TST 
Vehicle……………………………………………………………………………………...…VEH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x
  
 
 
 
 
CHAPTER 1 
 
BACKGROUND AND SIGNIFICANCE 
 
Etiology and illnesses associated with stress 
Depression can be defined as a diminished interest or pleasure in most activities 
(Cryan, 2002). At least 18.8 million Americans over the age of 18 are affected by a 
depressive disorder in a given year (NIMH, 2009) and an estimated 2% of American children 
between the ages of 7-12 have major depression (Harvard Medical School, 2002).  
Prolonged exposure to stress has been linked to the development of depression and several 
pathological conditions (NIOSH, 1999; Stojanovich, 2008). Stress is a multifactorial 
disruption of an organism’s physiological homeostasis that can be caused by a variety of 
external and internal stimuli that are predominately emotional, physical, psychological and 
environmental in nature. 
Currently, treatment for depression and other anxiety-derived illnesses are managed 
by antidepressants. Antidepressants can block the reuptake of neurotransmitters (NTs) in 
the brain or inhibit NT metabolism (Highfield, 2001). The antidepressant therapies currently 
available include tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors 
(SSRI) and monoamine oxidase inhibitors (MAO-I) (Long, 1998; Martinez, 2005). However, 
there are a growing number of human cases that report a resistance to the current 
antidepressant therapies (Fava, 2006). The endocannabinoid system has been proposed as 
an alternative therapy target for stress-induced depression. 
Despair and helplessness are behavioral responses of human depression 
(Borsini,1988) that can be monitored in mouse models. Mouse models serve as a suitable  
 
 system to investigate the effectiveness of antidepressant therapies used to treat human 
depression (Lucki, 2001b; Petit-Demouliere, 2005). Mouse models have been used to 
assess the effects of the endocannabinoid system (cannabinoid type 1 (CB1) receptor 
agonist, CB1 receptor antagonist, AEA reuptake blocker, or AEA metabolism inhibitor), 
evaluate behavior response to a novel stressor in the absence of learned helplessness 
developed during FST pre-exposure, and to measure CORT and AEA release in response 
to FST exposure. In the FST a common behavioral response that is recorded and scored is 
time spent immobile. Time spent immobile is defined as a lack of locomotor activity and is a 
stress coping behavior mice commonly display. 
In our study we determined whether pharmacological manipulation of CB1 receptor 
activity effects time spent immobile, therefore suggesting antidepressant-like properties in 
response to acute forced swim (FST) exposure.  In addition locomotor activity (LMA) was 
measured before (Pre-FST1), immediately after (Post-FST1), and a week after (LMA-FST1) 
the FST in open field tests, to determine if CB1 receptor activity can reverse the effects of 
FST exposure on LMA. 
Activation of the hypothalamic-pituitary-adrenal (HPA) axis 
Hyperactivation of the HPA axis has been linked to stress. The basic pathway 
involved in HPA axis activation has been outlined (Figure 1). In addition, the HPA axis 
activity can be altered with cannabinoids and reduce stress related behavioral responses 
(Tasker, 2004). In response to stressful psychological and physical stimuli, corticotrophin 
releasing hormone (CRH) is synthesized and released from the hypothalamus (Barna, 
2004;Tasker, 2004). CRH binds to receptors in the anterior pituitary and stimulates the 
synthesis and secretion of adrenocorticotropic hormone (ACTH). In turn, ACTH binds to 
receptors on the adrenal cortex, which activate adenylate cyclase (AC). Adenosine 
triphosphate (ATP) is converted into cyclic adenosine monophosphate (cAMP) in the  
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 presence of active AC.  
Increases in the intracellular levels of cAMP and several enzymes are involved in the 
biosynthesis and release of cortisol. The rodent equivalent to human cortisol is 
corticosterone (CORT). CORT release has been analyzed from rodents in response to FST 
exposure. In our laboratory we have observed a correlation between time spent immobile 
and CORT release. 
Endocannabinoid Signaling 
Endocannabinoids are endogenous neuromodulators involved in learning and 
memory, locomotor activity (LMA), depression, appetite, mood and behavior (Martin, 2002; 
Shearman, 2003; Barna, 2004; Hohmann, 2005; Hill, 2007; Benarroch, 2007; Griffith, 2009; 
LoVerme, 2008). The endocannabinoid system is composed of endocannabinoids that 
activate centrally and peripherally located cannabinoid receptors, cannabinoid type 1 (CB1) 
and cannabinoid type 2 (CB2) (Petit-Demouliere, 2005; Pertwee, 2006; Vaughan, 2006; 
LoVerme, 2008). Cannabinoid receptors are G-protein-coupled receptors (GPCR) 
responsible for inhibiting certain cellular functions and biological responses that include the 
release of neurotransmitters (NTs) from pre synaptic cells (Pertwee, 2006; Benarroch, 
2007). The CB1 receptor is the most abundant receptor in the central nervous system (CNS) 
and is located on pre synaptic neurons in the hippocampus (McLaughlin, 2007), 
hypothalamus (Arevalo, 2001), prefrontal cortex (Freund, 2003), periaqueductal gray 
(Vaughan, 2006), amygdale (Azad, 2003), and adipose tissue (Tzavara, 2003). 
When specific stimuli (i.e. electrical impulse, neurotrabsmitters (NTs)) are received by pre 
synaptic neurons, a signaling cascade is initiated, NT are released and act on receptors on 
post synaptic neurons. The NTs released initiate an intracellular signaling cascade in post 
synaptic neurons that facilitate the synthesis and release of endocannabinoids (Fig. 2; 
Vaughan, 2006; Benarroch, 2007). Anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) 
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 are two of the most widely studied endogenous endocannabinoids (Hohmann, 2005; 
Vaughan, 2006; Benarroch, 2007; Hill, 2007). 
Activation of the CB1 receptor by endogenous and exogenous cannabinoid ligands 
inhibits AC, which decreases cAMP levels and inhibits glutamate release (Pertwee, 2006; 
Benarroch, 2007). When this reaction occurs in the hypothalamic paraventricular nucleus 
(PVN) and supraoptic nucleus, synaptic input of CRH neurons in the PVN is inhibited 
(Tasker, 2004). The lack of glutamate release in response to CB1 receptor activation also 
effects postsynaptic cell desensitization (Di, 2003). The influx of calcium (Ca2+) is blocked, 
whereas the efflux of potassium (K+) is potentiated in pre synaptic cells in the presence of 
CB1 receptor activation. The increase in K+ efflux causes the pre synaptic cells to be 
hyperpolarized. Furthermore, activation of the CB1 receptor reduces arachidonic acid and 
activates mitogen-activated protein kinases (MAPK) and phosphatidylinositol-3 kinase 
(PI3K) pathways. Antidepressant screening ssays such as forced swim test (FST; Porsolt, 
1977; Porsolt, 1978; Borsini, 1988; Lucki, 2001a; Lucki, 2001b; Dalvi, 1999; Shearman, 
2003; Tzavara, 2003; Steiner, 2008a; Steiner, 2008b), tail suspension test, (TST; Gobbi, 
2005; Hill, 2005), and elevated plus maze (EPM; Haller, 2004; Griebel, 2005; Hill, 2007; 
Egashira, 2008) have been used to characterize the effects of endocannabinoids on 
immobility and locomotion. 
Summary 
The endocannabinoid system, specifically the CB1 receptor, is involved in stress 
behavioral responses such as time spent immobile and locomotion. Researchers report 
different findings about the influence of the endocannabinoid system, specifically the CB1 
receptor, on time spent immobile in the FST. The results may vary because of the different 
antidepressant screening tests, animal models, and the limited doses used. Furthermore, 
current anti-depressants are an effective form of treatment in less than half of those  
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 diagnosed with depression, and reduces locomotion activity. The impact of the 
endocannbinoid system on modulating the time spent immobile, and it effects on locomotor 
activity are unclear. Therefore, expanding our understanding of the endocannabinoid system 
will support its use as an alternative therapy for the treatment of depression without 
impairing locomotion. 
Significance 
Alterations in the time spent immobile and HPA axis hormone release observed in 
acute stress conditions response to CB1 receptor activity is similar to current antidepressant 
treatments. However, the effects of CB1 receptor activity on stress behavioral responses 
under acute FST conditions remains unclear. In addition, many of the studies investigating 
the impact of the endocannabinoid system do not include the effects of CB1 receptor 
activation on the locomotion concurrently. Our goal is to expand the range of AEA modifier 
doses, and extend our understanding how the endocannabinoid system modulates 
behavioral responses to the FST paradigm. The findings from this study will expand the 
understanding of the interaction between the endocannabinod system and behavioral 
responses to stress, and whether or not manipulation of the CB1 receptor influences 
locomotion in the presence or absence of stress exposure. 
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CHAPTER 2 
 
INTRODUCTION 
 
The cannabinoid type 1 (CB1) receptor is a G protein coupled receptor that is 
involved in modulating gamma-aminobutyric acid (GABA) and glutamate neurotransmitter 
release, calcium influx, and potassium eflux (Pertwee, 2006; Benarroch, 2007).  
Anandamide (AEA) is the endogenous agonist that binds to and activates the CB1 receptor.  
In addition, the CB1 receptor is involved in modulating a variety of behaviors such as 
learning and memory, locomotor activity, appetite, mood, anxiety, and depression (Martin, 
2002; Shearman, 2003; Barna, 2004; Tasker, 2004; Hohmann, 2005; Benarroch, 2007; Hill, 
2007; LoVerme, 2008; Griffith, 2009).  Currently, treatment for depression and other anxiety-
derived illnesses is managed with antidepressants, but because a growing number of 
human cases report a resistance to current antidepressant therapies (Fava, 2006), an 
alternative therapy is needed.  Antidepressants can modulate neurotransmitters in the brain 
by altering reuptake and inhibiting metabolism of dopamine, serotonin, and norepinephrine 
(Highfield, 2001).  Scientists are interested in exploring the modulatory effects of CB1 
receptor activation on responses to stress because CB1 receptor activation has potential 
applicability as a possible therapeutic treatment for stress and depression to human.   
The effect of CB1 receptor activation on responses to stress is unclear because 
different behavioral assays have been used to determine the impact of the endocannabinoid 
system on behavioral responses to stress (Bowers, 2008).  For example, Shearman (2003) 
demonstrated that CB1 receptor agonism increased the time spent immobile in the tail 
suspension test (TST), a behavioral assay that has been used to examine stress as well as  
 
 the effects of antidepressants.  Other research suggests that agonism (Jiang, 2005; 
Adamczyk, 2008; El-Alfy, 2010) and antagonism (Adamczyk, 2008; Takahashi, 2008) of the 
CB1 receptor can reduce time spent immobile in the forced swim test (FST), another 
behavioral assay that has been used to examine the activity of potential antidepressants.  
However, Rutkowska (2006) reported that CB1 receptor activation had no effect on time 
spent immobile in the FST.  The culmination of all of this research suggests that further 
examination of CB1 receptor activation and behavioral responses to stress are needed.   
There is limited information regarding the effect of CB1 receptor activation on 
locomotor activity (LMA).  Data suggest that high concentrations of AEA, an endogenous 
CB1 receptor ligand, result in sedation (Meybohm, 2008), which can, in turn, decrease LMA.  
Moreover, increases in AEA concentration can cause hypothermia, which can also decrease 
LMA and lead to immobility (Mogil, 1996; McLaughlin, 2003; Drugan, 2005).  It is evident 
that understanding the effects of CB1 receptor activation on LMA immediately after stress 
exposure is necessary to better understand the impact of CB1 receptor activation on 
behavioral responses to stress. 
One approach to studying the effects of CB1 receptor activation on behavioral 
responses to stress and locomotion are to use an animal model that will examine the effects 
of various doses of endocannabinoid AEA modifiers.   Endocannabinoid AEA modifiers 
indirectly activate CB1 receptors by increasing the concentration of AEA (Beltramo, 1997; 
Kathuria, 2003).  As a result, AEA modifiers increase the probability of AEA binding to CB1 
receptors and activating CB1 receptors.  The mechanisms known to increase AEA 
concentrations include 1) inhibition of AEA reuptake into neuronal cells and 2) inhibition of 
fatty acid amide hydrolase (FAAH) metabolism.  AM404, which block the reuptake of AEA 
into neuronal cells, and URB597, which inhibits the enzymatic activity of FAAH, are 
endocannabinoid modifiers that are known to increase AEA concentrations (Beltramo, 1997;  
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 Kathuria, 2003), and thereby increase CB1 receptor activity.  Some reports show that 
manipulating of AEA with URB597 and AM404 either decreases the behavioral response to 
FST stress (Gobbi, 2005; Hill, 2005a; Adamczyk, 2008), or has no effect (Naidu, 2008).  
Activating CB1 receptors indirectly with endocannabinoid AEA modifier, rather than direct 
ligands, may provide a better assessment of CB1 receptor activation in response to stress.  
The effects of CB1 receptor activity on behavioral responses to stress under acute 
conditions remains unclear.  In addition, many of the studies investigating the impact of the 
endocannabinoid system do not include the effects of CB1 receptor activation on LMA 
concurrently.  We hypothesize that the endocannabinoid system, specifically the CB1 
receptor, regulates behavioral responses to stress in C57Bl/6 mice as observed in the FST 
and open field test.  To test our hypothesis we 1) validated the FST paradigm assay as a 
screen for potential antidepressants; 2) examined the effects of a range of doses of URB597 
and AM404 by scoring the time spent immobile in response to FST exposure; and 3) 
assessed the effects of URB597 and AM404 on LMA by measuring a variety of locomotor 
assessments in the open field test.  Understanding the effect of CB1 receptor activation on 
behavioral responses to stress will aid in understanding the CB1 receptor in the onset and 
modulation of responses to stress and locomotion. 
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CHAPTER 3 
MATERIALS AND METHODS 
 
Animals 
Adult male C57BL/6 mice were purchased from Jackson Labs (Raleigh, NC; 10 
weeks of age upon delivery), for these studies.  The age of the mice during these studies 
was between 3 and 6 months.  All mice were group housed (four per cage) in standard 
Plexiglass cages in a colony room maintained on a reversed 12-hr light/dark cycle (lights on 
at 7:00 p.m., lights off at 7:00 a.m.).  Mice had continuous access to food and water 
throughout the study and were habituated to the intraperitoneal (i.p.) injection procedure 
(handling) and the colony room environment for 2 weeks prior to any experimental 
manipulation.  Mice were exposed to the testing environment for at least two days prior to 
the initiation of an experiment.  All testing procedures were conducted during the dark cycle 
between 10:00 a.m. and 3:00 p.m.  The “Guide for the Care and Use of Laboratory Animals” 
(National Research Council, National Academy of Sciences, Washington, D. C., 1996) was 
adhered to during all test sessions.  
Forced Swim Test (FST) Procedure 
The FST assay was used to measure and analyze behavioral responses to stress.  
The FST parameters included a glass cylinder filled with 3000 mL of water at 25 + 1˚C.  The 
water was changed between each FST session.  Each FST session was recorded for 6 min 
(JVC camcorder) and time spent immobile was measured in the FST assay.  Time spent 
immobile in the FST was defined as a lack of forearm or hind leg movement, or minimal 
body movement to keep their head and body afloat.  A stopwatch was used to score to the   
nearest second. 
 On the day of testing, mice received an intraperitoneal (i.p.) injection desipramine 
(DMI) (10 mg/kg and 20 mg/kg), AM404 (0.32-3.2 mg/kg), or URB597 (0.03-3.2 mg/kg).  
Drugs were administered 30 min prior to FST exposure. The full 6 min of each FST session 
was scored and analyzed.  The time spent immobile in the FST session was expressed as 
the mean + standard error of the mean (SEM). 
Open Field Test Procedure 
LMA was assessed in an LAC (28.6x28.6x20.7cm; Med-Associates, St. Albans, VT).  
Infrared photobeams in the LAC were spaced 5/8 of an inch apart.  LMA was defined as a 
disruption of 3 consecutive photobeams.  Interruptions of the photobeams indicated 
horizontal activity as measured in distance traveled and were expressed in centimeters 
(cm).  The parameters assessed for the present study were total distance traveled (cm), the 
average velocity (cm/s), number of entries into the center zone (#), and time spent in the 
center zone (min).  Immediately after the LMA session, the mice were removed from the 
LAC and returned to their homecage.  Between each LMA session, the LAC’s were cleaned 
with 70% ethanol and dried.  The Activity Monitor software program was used to analyze the 
data collected (Med-Associates, St. Albans, VT).   
Prior to the day of testing, each mouse was conditioned to the open field test for 1 hr. 
The mice were placed in the center of the LAC and allowed free movement.  After 
conditioning, the mice were returned to their home cage.  On the day of testing, each mouse 
was exposed to the open field test prior to the FST session (Pre-FST1) in order to determine 
baseline activity levels.  For Pre-FST1, each mouse was placed in a LAC for 1 hr before the 
FST session, then returned to its home cage.  The initial 30 min of the open field test was 
analyzed.  The mice then received an i.p. injection 30 min before the FST session (see FST 
Procedure), and immediately after the FST session, the mice were towel dried and placed in 
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 the LAC for 30 min (Post-FST1).  Following the open field test, the mice were returned to 
their homecage.  A week after the FST session, each mouse received an i.p. injection 30 
min prior to the open field test, and their LMA was recorded for 30 min (LMA-FST1).  
Following the open field test, the mice were returned to their homecage.  The mice received 
either DMI (10 mg/kg and 20 mg/kg), AM404 (0.32-3.2 mg/kg), or URB597 (0.03-3.2 mg/kg) 
prior to testing.  The influence of CB1 receptor activity on the behavioral response to FST 
exposure on LMA was recorded and analyzed using change difference analysis.   
Drugs and Treatment 
URB597 was provided by National Institutes on Drug Abuse (NIDA; Bethesda, MD).  
DMI, an anti-depressant, was purchased from Sigma-Aldrich (St. Louis, MO) and AM404 
from Tocris (Ellisville, MO).  URB597 and AM404 were dissolved in an ethanol, alkamuls, 
and 0.9% saline solution (1:1:18) combination.  DMI was dissolved in 0.9% saline solution.  
Drugs were administered through i.p. injections at a volume of 10 mg/ml. 
Data analysis 
The data for each test group included the mean + SEM for 1) time spent immobile; 2) 
total distance traveled; 3) average velocity; 4) number of entries into the center zone; and 5) 
time spent in the center zone.  The statistical significance for time spent immobile was 
analyzed using SAS and SPSS 18.0 software and one-way analysis of variance (ANOVA).  
Student t-tests were used when appropriate to compare the effect of treatment on time 
spent immobile.  Significance was set at a p value < 0.05.  The effect of each compound on 
the distance traveled, the average velocity, the number of entries into the center zone, and 
time spent in the center zone were analyzed using the one-way ANOVA.  The one-way 
ANOVA calculated the overall statistical difference between the doses tested and vehicle for 
each LMA session (Pre-FST1, Post-FST1, and LMA-FST1).  Significance was set at a p 
value < 0.05.  Post-hoc analysis calculated the statistical difference between the individual  
11 
 doses tested and vehicle for each LMA session.  Significance was set at a p value < 0.05.   
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CHAPTER 4 
RESULTS 
A. EFFECT OF THE FORCED SWIM TEST ON BEHAVIORAL RESPONSES 
Validation of the FST paradigm with DMI  
Figure 3 shows the effects of 10 mg/kg and 20 mg/kg of desipramine (DMI), on time 
spent immobile in the FST paradigm.  One-way ANOVA revealed a significant decrease for 
time spent immobile at 10 mg/kg of DMI for the full 6 min FST session (F(2,21)=4.867, 
p=0.013).  In contrast, 20 mg/kg of DMI did not decrease time spent immobile during the full 
6 min (F(2,21)=4.867, p>0.05).  These results validate the FST procedure with 10 mg/kg of 
DMI.  Therefore, this procedure will be used to screen potential antidepressants in future 
pharmacological studies.  
Effects of URB597 on time spent immobile 
Figure 4 shows the effect of URB597 on time spent immobile in the FST paradigm.  
One-way ANOVA analysis, followed by an unpaired t-test analysis revealed a significant 
increase in time spent immobile at 0.32 mg/kg of URB597 (p=0.016) and a significant 
decrease at 1.0 mg/kg (p=0.001) and 3.2 mg/kg of URB597 (p=0.001).  These findings 
suggest that manipulating AEA concentrations with URB597 produced biphasic effects for 
time spent immobile.  
Effects of AM404 on time spent immobile   
 
Figure 5 shows the effects of AM404 on time spent immobile in the FST paradigm.  
One-way ANOVA, followed by an unpaired t-test analysis revealed a significant decrease for 
time spent immobile at 1.0 mg/kg of AM404 (p=0.039), but no effects at 0.32 mg/kg or 3.2  
 
 mg/kg of AM404. 
B. EFFECT OF THE FORCED SWIM TEST ON LOCOMOTOR ACTIVITY 
Effect of DMI and FST1 exposure on locomotor activity 
In a previous experiment we validated the FST paradigm with 10 mg/kg of DMI and 
showed that DMI decreased time spent immobile (Figure 3).  The effect of 10 mg/kg of DMI 
on time spent immobile in the FST paradigm was repeated, and one-way ANOVA revealed 
a significant reduction for time spent immobile in response to 10 mg/kg of DMI (F(1,15) =6.106,  
p=0.026; Appendix A).   These data confirm the reduction in time spent immobile in the FST 
paradigm in response to DMI.  
Figure 6 shows the effect of DMI on distance traveled immediately after FST 
exposure (Post-FST1) and a week after FST exposure (LMA-FST1).  One-way ANOVA 
analysis revealed that FST exposure sharply reduced distance traveled in Post-FST1, and 
10 mg/kg of DMI did not reverse the decrease in distance traveled (F(1,17)=0.663, p=0.427; 
Table 1).  Importantly, 10 mg/kg of DMI significantly decreased distance traveled in LMA-
FST1 (F(1,17)=8.791, p=0.009; Table 1).   These results indicate that although 10 mg/kg of 
DMI decreased time spent immobile in the FST, it is likely that these effects were not due to 
an overall increase in locomotor activity (LMA). 
Effect of URB597 and FST1 exposure on locomotor activity 
Figure 7 shows the effects of URB597 on distance traveled for Post-FST1 and LMA-
FST1 using the open field test.  One-way ANOVA analysis revealed that FST exposure 
sharply reduced distance traveled in Post-FST1, but the URB597 doses used did not 
reverse the these effects (Table 1).  In addition, a URB597 dose dependent increase for 
distance traveled during LMA-FST1 was observed (F(5,48)=2.722, p=0.040; Table 1). 
Specifically, Post hoc analysis revealed a significant increase in distance traveled was 
observed at 0.32 mg/kg (p= 0.027), 1.0 mg/kg (p=0.003), and 3.2 mg/kg (p=0.010) when   
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 compared to vehicle LMA (Table 1).  These findings suggest that FST exposure affected 
distance traveled in the open field test, and URB597 was unable to reverse the effect (Post-
FST1).  Furthermore, URB597 enhanced LMA in a dose dependent manner in the absence 
of stress (LMA-FST1).  Therefore, it is likely that the increase in time spent immobile at 0.32 
mg/kg of URB597 is not due to overall changes in LMA.  However, the decrease in time 
spent immobile at 1.0 mg/kg and 3.2 mg/kg of URB597 may be explained by the changes in 
LMA.   
Effect of AM404 and FST1 exposure on locomotor activity 
Figure 8 shows the effect of AM404 and FST exposure on distance traveled in Post-
FST1 and LMA-FST1. One-way ANOVA analysis revealed that FST exposure sharply 
reduced distance traveled in Post-FST1, but AM404 did not reverse these effects (Table 1).  
However, 3.2 mg/kg of AM404 significantly decreased the distance traveled in LMA-FST1 
(F(1,28) =12.764, p=0.001; Table 1).  Therefore, the dose of AM404 (1.0 mg/kg) that 
decreased time spent immobile in the FST paradigm, did not alter locomotion during LMA-
FST1. 
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CHAPTER 5 
 
DISCUSSION 
 
The primary goals of these experiments were to employ the forced swim test (FST) 
to screen for the antidepressant effects of the endocannabinoid system, specifically CB1 
receptor activity, and to assess CB1 receptor activity on locomotor activity (LMA).  The main 
findings of the present study were that 1) pharmacological manipulation of cannabinoid type 
1 (CB1) receptors with AEA modifiers and with DMI reduced time spent immobile in a FST at 
25°C; 2) selected doses of AM404 and DMI reduced distance traveled in the open field test 
in LMA-FST1 (a week after FST exposure); 3) neither URB597 nor AM404 reversed the 
immediate effects of FST exposure on LMA; 4) the doses of DMI and AM404 that decreased 
time spent immobile did not produce parallel increases in LMA; and 5) the doses of URB597 
and AM404 that were examined did not alter the average velocity, time in the center zone, 
nor the number of center zone entries compared to vehicle.  
DMI reduced time spent immobile at the doses that did not increase LMA 
 It is well established that FST exposure is sufficient to screen for the potential effects 
of drugs as a treatment for depression (Porsolt, 1977; Porsolt, 1978).  Here we report that 
10 mg/kg of DMI reduced time spent immobile in response to FST exposure in two 
independent experiments. Our results are consistent with published data in which the 
greatest decrease in time spent immobile was observed in C57Bl/6 mice in response to 10 
mg/kg DMI and FST exposure at 25°C (Figure 3; Lucki, 2001; Hill, 2005a).  Therefore, we 
established an FST paradigm to screen potential antidepressants. 
The relationship between time spent immobile and locomotion is unclear; however,  
 studies show that decreases in time spent immobile lead to increases in time spent 
swimming suggesting a complementary relationship (Gobbi, 2005).  The assessment of LMA 
after stress and in response to drug administration remains to be elucidated.  We observed 
a significant decrease in distance traveled following 10 mg/kg of DMI in LMA-FST1, 
consistent with the current literature (Figure 6; Pähkla, 2000).  Moreover, 10 mg/kg of DMI 
did not reverse the large decreases in LMA observed following FST exposure; however, 10 
mg/kg of DMI decreased the number of center zone entries in Post-FST1 (F(1, 17)=9.502, 
p=0.007; Appendix C) and LMA-FST1 (F(1, 17)=9.938, p=0.007; Appendix C), and the time in 
the center zone in Post-FST1 (F(1, 17)=9.139, p=0.008; Appendix D).  DMI did not alter the 
average velocity compared to VEH (Appendix B).  These data indicate that although DMI 
increased mobility in the FST paradigm, these increases in mobility were not explained by 
increases in distance traveled.  Furthermore, the antidepressant effects of DMI are seen in 
the presence of stress.  
URB597 reduced time spent immobile at the doses that did alter LMA 
To examine the role of the endocannabinoid system on responses to stress, 
increasing doses of URB597 (0.03-3.2 mg/kg), a fatty acid amid hydrolase (FAAH) 
metabolism inhibitor, were used.  URB597 increases AEA concentration in post synaptic 
neurons by inhibiting AEA metabolism by FAAH (Kathuria, 2003).  We show 0.32 mg/kg of 
URB597 significantly increased time spent immobile, whereas 1.0 mg/kg and 3.2 mg/kg of 
URB597 significantly reduced time spent immobile in the 25°C FST.  The increase in time 
spent immobile with 0.03-0.32 mg/kg of URB597 is in contrast to reports indicating that 
URB597 decreases time spent immobile in response to FST exposure (Gobbi, 2005; Hill, 
2007; Adamczyk, 2008).  The increase in time spent immobile in response to 0.03-0.32 
mg/kg of URB597 may be the result of an increase in AEA concentration and CB1 receptor 
activity, therefore leading to sedation (Meybohm, 2008).  
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 Additional reasons for this discrepancy includes 1) different species and strains used 
(Borsini, 1988; Hall, 2001); 2) different stressor paradigm used (Campos, 2010); 3) the effect 
of handling on behavioral responses prior to testing (Pryce, 2005; Burn, 2008); and 4) 
changes in CB1 receptor availability.  It is also plausible that the increase in time spent 
immobile at 0.03-0.32 mg/kg URB597 was caused by changes in CB1 receptor availability.  
Glucocorticoids are synthesized and released in response to stress.  Reports show that 
glucocorticoids negatively regulate CB1 receptor transcription (Maileux, 1993) and density 
(Hill, 2008), therefore reducing receptor availability and increasing AEA binding to non-CB1 
receptors.  Therefore, it is possible that stress exposure and activation of the CB1 receptor 
may influence glucocoticoids and response to stress.  On the other hand, the increase in 
CB1 receptor activity may have resulted in desensitization and down regulation of CB1 
receptors on pre synaptic neurons, which has been reported in response to chronic 
unpredictable mild stress (Hill, 2005b).  The biphasic effect of URB597 on time spent 
immobile is not uncommon.  El-Alfy (2010) reports a biphasic effect of delta-9 
tetrahydrocannabinol (THC), an exogenous CB1 receptor agonist, on time spent immobile in 
an acute FST and the tail suspension test (TST).  The influence of acute stress exposure on 
CB1 receptor expression is not well characterized, and may explain the behavioral 
responses we discovered in these studies. These data suggest that further investigation of 
the concentration of AEA in response to stress exposure and URB597 are needed.  
Furthermore, the decrease in time spent immobile from 0.32-3.2 mg/kg of URB597 
may be the results of another enzyme compensating for the loss of FAAH to metabolize 
AEA, AEA binding to and activating cannabinoid type 2 (CB2) receptor or a non-cannabinoid 
receptor to decrease time spent immobile.  Stress exposure may alter lipid metabolism 
(Poleszak, 2008).  Altering the metabolism of AEA with increasing doses of URB597, in 
addition to stress exposure, may have contributed to the difference in time spent immobile in  
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 our studies. 
  We show that 1.0 mg/kg and 3.2 mg/kg of URB597 decreased time spent immobile 
in the FST (Figure 4), however, its effects on LMA is unknown.  Studies show significant 
reductions in locomotion and sedation with high concentrations of AEA and CB1 receptor 
activity in the absence of stress (Meybohm, 2008).  Reductions in locomotion and sedation 
would be a confounding response in evaluating AEA modifiers in the FST to measure 
predictive antidepressant behavioral responses.  We report a significant dose dependent 
increase for distance traveled in response to 0.32-3.2 mg/kg of URB597 was observed in 
LMA-FST1 (Figure 7).  These data are inconsistent with the findings by Adamczyk (2008), 
which show no effect of URB597 on distance traveled in the absence of stress exposure. 
URB597 did not alter the average velocity compared to VEH (Appendix B).  This finding is 
unique because mice show an effect of URB597 in the absence of stress (LMA-FST1), 
therefore, supporting the involvement of the CB1 receptor in LMA as measured in the open 
field test.  Also, one-way ANOVA, followed by Post hoc analysis revealed a significant 
increase in the number of center zone entries in LMA-FST1 at 0.32 mg/kg (p=0.032), 1.0 
mg/kg (p= 0.013), 3.2 mg/kg (p=0.16) compared to vehicle (Appendix C).  Furthermore, one-
way ANOVA, followed by Post hoc analysis revealed a significant increase for the time 
spent in the center zone in at 0.03 mg/kg (p=0.000) in Post-FST1 (Appendix D) and at 0.32 
mg/kg (p=0.009) in LMA-FST1 (Appendix D) compared to vehicle.  It remains unclear 
whether the behavioral responses observed in the FST are a result of AEA metabolism 
inhibition, increasing AEA concentrations, or activation of CB1 receptor; thus further 
investigation is needed.  
AM404 reduced time spent immobile at the doses that did not increase LMA 
An alternative approach to examine the effects of the endocannabinoid system on 
the response to stress is to study the effects of AM404 (0.32-3.2 mg/kg), an AEA reuptake 
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 inhibitor. AM404 increases AEA concentrations by preventing the reuptake of AEA into post 
synaptic neurons and preventing its metabolism, therefore increasing the activation of CB1 
receptors (Beltramo, 1997; Giuffrida, 2000).  We showed that 0.32-3.2 mg/kg of AM404 
produced a trend towards a decreased in time spent immobile in response to FST exposure 
at 25°C, and that 1.0 mg/kg of AM404 significantly decreased time spent immobile under 
these conditions (Figure 5).  These findings are consistent with those that report that AM404 
decreases time spent immobile in response to FST exposure (Hill, 2005a; McLauglin, 2007; 
Adamczyk, 2008). These data indicate that indirect activation of the CB1 receptor has 
antidepressant properties in the FST paradigm.   
It has been established that the CB1 receptor activity modulates locomotion.  The 
effect of AM404 on AEA and CB1 receptor activity and the relationship between time spent 
immobile and LMA are unknown.  We report that 3.2 mg/kg of AM404 significantly 
decreased distance traveled in LMA-FST1 (p=0.001; Figure 8).  These results that are 
consistent with the findings that AM404 (Gonzalez, 1999) and AEA (Fride, 1993) decrease 
motion and increase time spent inactive in the open field test.  However, our results are in 
contrast with the data of Adamczyk (2008), which shows no effect of AM404 on distance 
traveled.  These data suggest that 1.0 mg/kg of AM404 not only decreased time spent 
immobile in the FST, this dose of AM404 did not alter LMA in LMA-FST1.  AM404 did not 
alter the average velocity (Appendix B), number of entries into the center zone (Appendix 
C), time spent in the center zone (Appendix D) compared to VEH.  Therefore, 1.0 mg/kg of 
AM404 has the potential to be a therapeutic drug for depression, based on our screening 
assay, and did not alter LMA.  The mechanism of action of AM404 to affect CB1 receptor 
activity differs in its effects on LMA in the presence or absence of FST exposure; therefore, 
further investigation into how AM404 modulates time spent immobile in the FST is needed.   
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CHAPTER 6 
 
CONCLUSION 
 
Taken together, these studies demonstrate for the first time that AEA modifiers 
URB597, AM404, and the antidepressant DMI are effective at reducing time spent immobile 
in response to acute FST exposure.  Moreover, employing different mechanisms to increase 
the concentration of AEA using AEA modifiers (URB597 and AM404) may modulate time 
spent immobile and LMA differently, and these differences may be the result of physiological 
changes caused by FST exposure.  As such, activation of the CB1 receptor indirectly with 
AEA modifiers may have some beneficial properties to reduce behavioral responses to 
stress.  Further investigation is needed to determine if the compounds used are effective as 
potential antidepressant and whether or not they have side effects in human studies.   
 
 
 
 
 
 
 
 
 
 
 
 
 LIST OF FIGURES 
 
Figure 1. Schematic of Hypothalamus-Pituitary Adrenal (HPA) axis stress response 
cascade. The onset of stress initiates the synthesis and release of corticotrophin releasing 
hormone (CRH). CRH binds to CRH receptors, located on the anterior pituitary, and 
stimulates the synthesis and release of adrenocorticotropic hormone (ACTH). ACTH binds 
to ACTH receptors located on the adrenal cortex, and stimulates the release of 
corticosterone (CORT). 
 
Figure 2. Schematic representation of endocannabinoid signaling. Anandamide (AEA), 
an endogenous CB1 receptor ligand, is produced from a membrane bound molecule N-
acylphophatidylethanolamine (NAPE) upon cleavage by phospholipase D (PLD). AEA is 
released from the postsynaptic neuron and binds to CB1 receptors on the pre synaptic 
neuron. CB1 receptor activation inhibits adenylate cyclase (AC), calcium (Ca 2+) influx, and 
glutamate and gamma-aminobutyric acid (GABA) neurotransmitter release from presynaptic 
neurons. Activation of the CB1 receptor positively regulates potassium (K +) efflux. In a 
retrograde fashion, AEA disassociates from the CB1 receptor and enters in to the 
postsynaptic neuron, in which it is metabolized by a fatty acid amide hydrolase (FAAH) into 
arachidonic acid and ethanolamine.  
 
Figure 3.  Effects of 10 mg/kg and 20 mg/kg desipramine (DMI) on time spent 
immobile in FST1 (25° C).  C57Bl/6 mice received vehicle (0.9% saline) or desipramine 
(DMI) prior to FST exposure. Time spent immobile for the full 6 min FST session.  
Abscissae, VEH and DMI.  Ordinates, time spent immobile measured in seconds.  Data 
were calculated using the mean + SEM of two independent experiments.  An asterisk 
indicates statistical significance between the FST paradigms used by a p value < 0.05 (*). 
n=5-12. 
 
Figure 4.  Effects of URB597 on time spent immobile in FST1 (25° C).  C57Bl/6 mice 
received vehicle (VEH), 0.03 mg/kg, 0.1 mg/kg, 0.32 mg/kg, 1.0 mg/kg, or 3.2 mg/kg of 
URB597 prior to FST exposure. Time spent immobile for the full 6 min of the FST session.  
Abscissae, VEH and URB597.  Ordinates, time spent immobile measured in seconds.  Data 
were calculated using the mean + SEM of three independent experiments.  An asterisk 
indicates statistical significance between the control and the treatment used, p value < 0.05 
(*).  n=8-10. 
 
Figure 5.  Effects of AM404 on time spent immobile in FST1 (25° C).  C57Bl/6 mice 
received vehicle, 0.32 mg/kg, 1.0 mg/kg, or 3.2 mg/kg of AM404 prior to FST exposure.  
Time spent immobile for the full 6 min of the FST session.  Abscissae, VEH and AM404.  
Ordinates, time spent immobile measured in seconds.  Data were calculated using the mean 
+ SEM of two independent experiments.  An asterisk indicates statistical significance 
between the control and the treatment used, a p value < 0.05 (*). n=8. 
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Figure 6. Effects of DMI on distance traveled in the open field test. C57Bl/6 mice 
received vehicle (VEH) and 10 mg/kg of desipramine (DMI). A) Baseline distance traveled 
recorded in the absence of drug administration and prior to FST1 exposure (Pre-FST1). B) 
Distance traveled recorded immediately following drug administration and FST1 exposure 
(Post-FST1).  C) Distance traveled recorded a week after FST1 exposure and in the 
presence of drug administration (LMA-FST1).  Abscissae, Groups of mice (1-2; A), VEH and 
DMI (B, C).  Ordinates, distance traveled measured in centimeters (cm).  The group 
numbers correspond to the drug administered to each group during the Post-FST1 and 
LMA-FST1 experiments (1=VEH, 2=10 mg/kg of DMI mg/kg).   Data were calculated using 
the mean + SEM of two independent experiments.  An asterisk indicates statistical 
significance between the control and the treatment used, a p value < 0.05 (*). n=9-10. 
 
Figure 7. Effects of URB597 on distance traveled in the open field test. C57Bl/6 mice 
received vehicle (VEH), 0.03 mg/kg, 0.1 mg/kg, 0.32 mg/kg, 1.0 mg/kg, or 3.2 mg/kg of 
URB597. A) Baseline distance traveled recorded in the absence of drug administration and 
prior to FST1 exposure (Pre-FST1). B) Distance traveled recorded immediately following 
drug administration and FST1 exposure (Post-FST1).  C) Distance traveled recorded a week 
after FST1 exposure and in the presence of drug administration (LMA-FST1).  Abscissae, 
Groups of mice (1-6; A), VEH and URB597 (B, C).  Ordinates, distance traveled measured 
in centimeters (cm).  The group numbers correspond to the drug administered to each group 
during the Post-FST1 and LMA-FST1 experiments (1=VEH, 2=0.03 mg/kg URB597, 3=0.1 
mg/kg URB597, 4=0.32 mg/kg URB597, 5=1.0 mg/kg URB597, 6=3.2 mg/kg URB597).   
Data were calculated using the mean + SEM of three independent experiments.  An asterisk 
indicates statistical significance between the control and the treatment used, a p value < 
0.0125 (*). n=8-10. 
 
Figure 8. Effects of AM404 on distance traveled in the open field test. C57Bl/6 mice 
received vehicle (VEH), or 0.32 mg/kg, 1.0 mg/kg, or 3.2 mg/kg of AM404. A) Baseline 
distance traveled recorded in the absence of drug administration and prior to FST1 
exposure (Pre-FST1). B) Distance traveled recorded immediately following drug 
administration and FST1 exposure (Post-FST1).  C) Distance traveled recorded a week after 
FST1 exposure and in the presence of drug administration (LMA-FST1).  Abscissae, Groups 
of mice (1-4; A), VEH and doses of AM404 (B, C).  Ordinates, distance traveled measured in 
centimeters (cm).  The group numbers correspond to the drug administered to each group 
during the Post-FST1 and LMA-FST1 experiments (1=VEH, 2=0.32 mg/kg of AM404, 3=1.0 
mg/kg of AM404, 4=3.2 mg/kg of AM404).    Data were calculated using the mean + SEM of 
two independent experiments.  An asterisk indicates statistical significance between the 
control and the treatment used, a p value < 0.0125 (*). n=8. 
 
 
 
 
 
23 
  
Figure 1 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24
 Figure 2 
 
 
  
 
 
 
 
 
 
 
 
 
 
25
  
Figure 3 
 
 
VEH 10 20 
0
50
100
150
Desipramine (mg/kg)
Im
m
o
bi
le
 
(S
ec
)
 
 
 
 
 
 
 
 
 
 
 
26 
* 
  
Figure 4 
  
 
 
VEH 0.03 0.1 0.32 1.0 3.2
0
50
100
150
URB597 (mg/kg)
Im
m
o
bi
le
 
(S
ec
)
 
 
 
 
 
 
 
 
 
 
27 
* 
* 
* 
 Figure 5 
 
 
 
VEH 0.32 1.0 3.2
0
50
100
150
AM404 (mg/kg)
Im
m
o
bi
le
 
(S
ec
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
* 
  
Figure 6 
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 Table 1. Locomotor activity assessment of distance traveled (cm) mean values (+ 
SEM) for treatment with vehicle, 10 mg/kg of DMI, 0.03 mg/kg-3.2 mg/kg of URB597, 
and 0.1 mg/kg-3.2 mg/kg of AM404 measured in the open field test (30 min session).  
  
 
Treatment 
 
Pre-FST1 
 
Post-FST1 
 
LMA-FST1 
Vehicle 2805.0 (+ 359.5) 419.6 (+ 114.8)   2348.0 (+ 218.1) 
10 DMI 3181.0 (+ 202.9) 197.3 (+ 73.80) *1579.0 (+ 181.1) 
    
Vehicle 2805.0 (+ 359.5) 419.6 (+ 114.8) 2348.0 (+ 218.1) 
0.03 URB597 3405.0 (+ 295.3) 588.3 (+ 127.8)   2859.0 (+ 448.8) 
0.1   URB597 3295.0 (+ 321.3) 524.9 (+ 120.5)        2977.0 (+ 279.0) 
0.32 URB597 3504.0 (+ 407.1) 540.3 (+ 151.2)      *3329.0 (+ 303.1) 
1.0   URB597 3875.0 (+ 306.7) 460.1 (+ 46.74) *3800.0 (+ 166.3) 
3.2   URB597 3205.0 (+ 311.5) 613.7 (+ 63.51) *3564.0 (+ 303.5) 
    
Vehicle 3319.0 (+ 248.8) 666.3 (+ 87.86) 3182.0 (+ 202.6) 
0.32 AM404 3381.0 (+ 272.3)    659.2 (+ 153.60) 2953.0 (+ 279.5) 
1.0   AM404 3277.0 (+ 266.6) 491.7 (+ 63.26) 2979.0 (+ 322.3) 
3.2   AM404 3150.0 (+ 286.3) 418.3 (+ 78.52) *1832.0 (+ 189.1) 
Statistical significance determined by one-way ANOVA analysis of the change 
difference: * p value < 0.05 
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 APPENDIX 
 
Appendix A.  Effects of DMI on time spent immobile in FST1 (25° C).  C57Bl/6 mice 
received vehicle or 10 mg/kg of DMI prior to FST exposure. Time spent immobile for the full 
6 min of the FST session.  Abscissae, VEH and DMI.  Ordinates, time spent immobile 
measured in seconds.  Data were calculated using the mean + SEM.  An asterisk indicates 
statistical significance between the control and the treatment used, a p value < 0.05 (*). n=8-
9. 
 
Appendix B.  Effects of DMI, URB597, and AM404 on average velocity in the open field 
test.  C57Bl/6 mice received vehicle (VEH), 10 mg/kg of DMI, 0.03-3.2 mg/kg of URB597, or 
0.3203.2 mg/kg of AM404. A) Baseline center zone entries recorded in the absence of drug 
administration and prior FST1 exposure (Pre-FST1). B) Center zone entries recorded 
immediately following drug administration and FST1 exposure (Post-FST1).  C) Center zone 
entries recorded a week after FST1 exposure and following drug administration (LMA-
FST1).  Abscissae, Groups of mice (1-6; A), VEH, DMI, URB597, AM404 (B, C).  Ordinates, 
average velocity measured in centimeters per second (cm/sec).  The group numbers 
correspond to the drug administered to each group during the Post-FST1 and LMA-FST1 
experiments (DMI:1=VEH, 2=10 mg/kg of DMI; URB597: 1=VEH, 2=0.03 mg/kg of URB597, 
3=0.1 mg/kg of URB597, 4=0.32 mg/kg of URB597, 5=1.0 mg/kg of URB597; 6=3.2  mg/kg 
of URB597; AM404: 1=VEH, 2=0.32 mg/kg of AM404, 3=1.0 mg/kg of AM404, 4=3.2 mg/kg 
of AM404.  Data were calculated using the mean + SEM.  An asterisk indicates statistical 
significance between VEH and DMI, URB597, AM404, p value < 0.05 (*). n=8-10. 
 
Appendix C.  Effects of DMI, URB597, AM404 on center zone entries in the open field 
test.  C57Bl/6 mice received vehicle (VEH), 10 mg/kg of DMI, 0.03-3.2 mg/kg of URB597, or 
0.32-3.2 mg/kg AM404. A) Baseline center zone entries recorded in the absence of drug 
administration and prior FST1 exposure (Pre-FST1). B) Center zone entries recorded 
immediately following drug administration and FST1 exposure (Post-FST1).  C) Center zone 
entries recorded a week after FST1 exposure and following drug administration (LMA-
FST1).  Abscissae, Groups of mice (1-6; A), VEH, DMI, URB597, AM404 (B, C).  Ordinates, 
number of center zone entries measured in a cumulative number (#).  The group numbers 
correspond to the drug administered to each group during the Post-FST1 and LMA-FST1 
experiments (DMI:1=VEH, 2=10 mg/kg of DMI; URB597: 1=VEH, 2=0.03 mg/kg of URB597, 
3=0.1 mg/kg of URB597, 4=0.32 mg/kg of URB597, 5=1.0 mg/kg of URB597; 6=3.2  mg/kg 
of URB597; AM404: 1=VEH, 2=0.32 mg/kg of AM404, 3=1.0 mg/kg of AM404, 4=3.2 mg/kg 
of AM404.  Data were calculated using the mean + SEM.  An asterisk indicates statistical 
significance between VEH and DMI, URB597, AM404, p value < 0.05 (*). n=8-10. 
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 Appendix D.  Effects of DMI, URB597, AM404 on time in the center zone in the open 
field test.  C57Bl/6 mice received vehicle (VEH), 10 mg/kg of DMI, 0.03-3.2 mg/kg of 
URB597, 0.32-3.2 mg/kg of AM404. A) Baseline time in the center zone recorded in the 
absence of drug administration and prior FST1 exposure (Pre-FST1). B) Time in the center 
zone recorded immediately following drug administration and FST1 exposure (Post-FST1).  
C) Time in the center zone recorded a week after FST1 exposure and following drug 
administration (LMA-FST1).  Abscissae, Groups of mice (1-6; A), VEH, DMI, URB597, 
AM404 (B, C).  Ordinates, time in the center zone measured in minutes (min).  The group 
numbers correspond to the drug administered to each group during the Post-FST1 and 
LMA-FST1 experiments (DMI:1=VEH, 2=10 mg/kg of DMI; URB597: 1=VEH, 2=0.03 mg/kg 
of URB597, 3=0.1 mg/kg of URB597, 4=0.32 mg/kg of URB597, 5=1.0 mg/kg URB597; 
6=3.2  mg/kg of URB597; AM404: 1=VEH, 2=0.32 mg/kg of AM404, 3=1.0 mg/kg of AM404, 
4=3.2 mg/kg of AM404.  Data were calculated using the mean + SEM.  An asterisk indicates 
statistical significance between VEH and DMI, or URB597, p value < 0.05 (*). n=8-10. 
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